Assessment of follicular and serum VEGF and IGF-1 in ICSI patients: hMG vs rFSH

What Was Tested

The paper reports a study of IGF-1 LR3 and hCG (human chorionic gonadotropin), published as a randomized controlled trial.

To investigate the effect of recombinant follicular stimulating hormone (r-FSH) and human menopausal gonadotropin (hMG) on follicular microenvironment via assessment of follicular and serum vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) levels in intracytoplasmic sperm injection (ICSI) cycles.

Who Took Part

The study group was 20 patients.

PubMed indexes the participants as adults, women only.

Twenty-five patients underwent controlled ovarian hyperstimulation (COH) with r-FSH and 20 patients underwent with hMG.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

Designed as a prospective cohort study.

What Was Measured

The subject headings attached to it are Chorionic Gonadotropin, Cohort Studies, Follicle Stimulating Hormone, Follicular Fluid, Insulin-Like Growth Factor I, Pregnancy Rate and Sperm Injections, Intracytoplasmic.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 and hCG (human chorionic gonadotropin) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Clinical and experimental obstetrics & gynecology), a journal based in Singapore.

More context: the IGF-1 LR3 compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.